

# Randomised placebo controlled trial of outpatient cervical ripening with isosorbide mononitrate (IMN) prior to induction of labour - clinical trial with analyses of efficacy, cost effectiveness and acceptability

<b>Submission date</b> 13/06/2005	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 25/07/2005	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
<b>Last Edited</b> 16/03/2020	<b>Condition category</b> Pregnancy and Childbirth	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

Not provided at time of registration

## Study website

<https://www.charttrials.abdn.ac.uk/imop/index.php>

## Contact information

### Type(s)

Scientific

### Contact name

Dr Jane Norman

### Contact details

University of Glasgow Division of Developmental Medicine  
3rd Floor, Queen Elizabeth Building  
Glasgow Royal Infirmary  
10 Alexandra Parade  
Glasgow  
United Kingdom  
G31 2ER  
+44 (0)141 211 4708  
[j.e.norman@clinmed.gla.ac.uk](mailto:j.e.norman@clinmed.gla.ac.uk)

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**

RN04OB007

## **Study information**

### **Scientific Title**

Randomised placebo controlled trial of outpatient cervical ripening with isosorbide mononitrate (IMN) prior to induction of labour - clinical trial with analyses of efficacy, cost effectiveness and acceptability

### **Acronym**

IMOP

### **Study objectives**

Outpatient isosorbide mononitrate will result in a shorter inpatient stay before delivery, decreased costs to the health service, and greater maternal satisfaction with induction of labour, compared with placebo treatment

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

Not provided at time of registration

### **Study design**

Randomised controlled trial

### **Primary study design**

Interventional

### **Secondary study design**

Randomised controlled trial

### **Study setting(s)**

Hospital

### **Study type(s)**

Treatment

### **Participant information sheet**

Patient information can be found at: <https://www.charttrials.abdn.ac.uk/imop/pis.php>

### **Health condition(s) or problem(s) studied**

Cervical ripening prior to induction of labour

### **Interventions**

Isosorbide mononitrate 40 mg (or placebo) given vaginally 48 hours, 32 hours and 16 hours prior to scheduled admission for induction of labour.

### **Intervention Type**

Drug

### **Phase**

Not Specified

### **Drug/device/biological/vaccine name(s)**

Isosorbide mononitrate (IMN)

### **Primary outcome measure**

- i. Elapsed time interval from hospital admission to vaginal delivery (defined as the time from admission for inpatient induction or admission in labour to delivery)
- ii. Costs to the health service of induction of labour
- iii. Womens experience of induction of labour

### **Secondary outcome measures**

- iv. Operative delivery rates
- v. Incidence of unscheduled admission for reasons other than labour commencing
- vi. Duration and frequency of neonatal admissions to special care
- vii. Incidence of adverse maternal and fetal outcomes such as uterine hypercontractility, postpartum haemorrhage (maternal outcomes) and meconium stained liquor, five minute Apgar of less than seven (fetal outcomes)
- viii. Length of labour
- ix. Oxytocin augmentation rates
- x. Epidural usage
- xi. Proportion with unfavourable cervix at 24 hours after admission
- xii. Requirement for additional inpatient cervical ripening agent

### **Overall study start date**

01/02/2005

### **Completion date**

31/01/2007

## **Eligibility**

### **Key inclusion criteria**

- 1. Bishop score less than or equal to 6
- 2. Singleton pregnancy
- 3. Nulliparity
- 4. Gestation greater than or equal to 37 completed weeks
- 5. Willing to self administer vaginal tablets

### **Participant type(s)**

Patient

**Age group**

Adult

**Sex**

Female

**Target number of participants**

300

**Key exclusion criteria**

Fetal compromise of sufficient severity such that daily fetal monitoring is scheduled

**Date of first enrolment**

01/02/2005

**Date of final enrolment**

31/01/2007

## **Locations**

**Countries of recruitment**

Scotland

United Kingdom

**Study participating centre**

University of Glasgow Division of Developmental Medicine

Glasgow

United Kingdom

G31 2ER

## **Sponsor information**

**Organisation**

Greater Glasgow Health Board (North Glasgow University Hospitals Division) and The University of Glasgow (UK)

**Sponsor details**

Research and Development Office

4th Floor, Walton Building

Glasgow Royal Infirmary

84 Castle Street

Glasgow

United Kingdom  
G4 OSF  
+44 (0)141 211 0475  
fiona.graham.gri@northglasgow.scot.nhs.uk

**Sponsor type**

Hospital/treatment centre

**ROR**

<https://ror.org/05kdz4d87>

## Funder(s)

**Funder type**

Charity

**Funder Name**

Wellbeing (Charity) Ref. CT 2004

## Results and Publications

**Publication and dissemination plan**

Not provided at time of registration

**Intention to publish date****Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	25/07/2006		Yes	No
<a href="#">Results article</a>	results	01/08/2009		Yes	No